Cargando…

Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial

BACKGROUND: EXamining everolimus In a Study of Tuberous sclerosis 3 (EXIST-3) demonstrated significantly reduced seizure frequency (SF) with everolimus vs placebo. In this study, we evaluate the long-term efficacy and safety of everolimus for tuberous sclerosis complex (TSC)-associated treatment-ref...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franz, David N., Lawson, John A., Yapici, Zuhal, Ikeda, Hiroko, Polster, Tilman, Nabbout, Rima, Curatolo, Paolo, de Vries, Petrus J., Dlugos, Dennis J., Voi, Maurizio, Fan, Jenna, Vaury, Alexandra, Pelov, Diana, French, Jacqueline A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276348/ https://www.ncbi.nlm.nih.gov/pubmed/30564495 http://dx.doi.org/10.1212/CPJ.0000000000000514

Ejemplares similares

Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures
por: Franz, David N., et al.
Publicado: (2018)

Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives
por: Overwater, Iris E, et al.
Publicado: (2019)

Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2
por: Kwiatkowski, David J, et al.
Publicado: (2015)

Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2(+/−) Mice Is Superior to Everolimus Alone()
por: Yang, Jian, et al.
Publicado: (2017)

A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC)
por: Zöllner, Johann Philipp, et al.
Publicado: (2020)

Measuring Health-Related Quality of Life in Tuberous Sclerosis Complex – Psychometric Evaluation of Three Instruments in Individuals With Refractory Epilepsy
por: de Vries, Petrus J., et al.
Publicado: (2018)

TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study
por: de Vries, Petrus J., et al.
Publicado: (2018)

Fenfluramine HCl (Fintepla(®)) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study
por: Sullivan, Joseph, et al.
Publicado: (2020)

Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project
por: de Vries, Petrus J., et al.
Publicado: (2020)

Clinical response to everolimus in a patient with Hodgkin's lymphoma harboring a TSC2 mutation
por: Perini, G F, et al.
Publicado: (2016)

A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations
por: Devarakonda, Siddhartha, et al.
Publicado: (2021)

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study
por: Bissler, John J., et al.
Publicado: (2017)

Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation
por: Hwang, Su-Kyeong, et al.
Publicado: (2016)

UPLC-MS based integrated plasma proteomic and metabolomic profiling of TSC-RAML and its relationship with everolimus treatment
por: Wang, Zhan, et al.
Publicado: (2023)

The TSC1-TSC2 complex consists of multiple TSC1 and TSC2 subunits
por: Hoogeveen-Westerveld, Marianne, et al.
Publicado: (2012)

TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex
por: Kingswood, J. Chris, et al.
Publicado: (2021)

Everolimus for treatment of tuberous sclerosis complex‐associated neuropsychiatric disorders
por: Krueger, Darcy A., et al.
Publicado: (2017)

Efficacy and safety of Everolimus in children with TSC - associated epilepsy – Pilot data from an open single-center prospective study
por: Samueli, Sharon, et al.
Publicado: (2016)

Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing
por: Tyburczy, Magdalena E., et al.
Publicado: (2015)

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis
por: Bissler, John J., et al.
Publicado: (2018)

Seizure reduction in TSC2‐mutant mouse model by an mTOR catalytic inhibitor
por: Dhamne, Sameer C., et al.
Publicado: (2023)

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study
por: Franz, David N., et al.
Publicado: (2016)

Add‐on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy
por: Kuchenbuch, Mathieu, et al.
Publicado: (2020)

Proposal for an updated seizure classification framework in clinical trials
por: Steriade, Claude, et al.
Publicado: (2022)

LGG-18. EVEROLIMUS TREATMENT IN PEDIATRIC PATIENTS AFFECTED BY LOW-GRADE GLIOMAS (pLGG) NON-TSC, BRAF v600-WT
por: Cacchione, Antonella, et al.
Publicado: (2020)

Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures
por: Yang, Ming-Tao, et al.
Publicado: (2017)

Variants Within TSC2 Exons 25 and 31 Are Very Unlikely to Cause Clinically Diagnosable Tuberous Sclerosis
por: Ekong, Rosemary, et al.
Publicado: (2016)

Evidence for population variation in TSC1 and TSC2 gene expression
por: Jentarra, Garilyn M, et al.
Publicado: (2011)

Stick or twist: Everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic
por: Moloney, Patrick B., et al.
Publicado: (2021)

Understanding the impact of tuberous sclerosis complex: development and validation of the TSC-PROM
por: Müller, Annelieke R., et al.
Publicado: (2023)

Capturing seizures in clinical trials of antiseizure medications for KCNQ2‐DEE
por: Millichap, John J., et al.
Publicado: (2021)

Analysis of the TSC1and TSC2genes in sporadic renal cell carcinomas
por: Parry, L, et al.
Publicado: (2001)

Mutation spectrums of TSC1 and TSC2 in Chinese women with lymphangioleiomyomatosis (LAM)
por: Liu, Jie, et al.
Publicado: (2019)

Germline mutation of TSC1 or TSC2 gene in Chinese patients with bilateral renal angiomyolipomas and mutation spectrum of Chinese TSC patients
por: Jiangyi, Wang, et al.
Publicado: (2020)

Correction: Understanding the impact of tuberous sclerosis complex: development and validation of the TSC-PROM
por: Müller, Annelieke R., et al.
Publicado: (2023)

Regionally specific TSC1 and TSC2 gene expression in tuberous sclerosis complex
por: Li, Yi, et al.
Publicado: (2018)

Mutational analysis of TSC1 and TSC2 in Danish patients with tuberous sclerosis complex
por: Rosengren, Thomas, et al.
Publicado: (2020)

Correction: Mutation spectrums of TSC1 and TSC2 in Chinese women with lymphangioleiomyomatosis (LAM)
por: Liu, Jie, et al.
Publicado: (2020)

mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus
por: Petrasek, Tomas, et al.
Publicado: (2021)

Tsc2 mutation rather than Tsc1 mutation dominantly causes a social deficit in a mouse model of tuberous sclerosis complex
por: Kashii, Hirofumi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a96glgdfi1er532lgr6paaa1ja